Hong Kong
May 16, 2024
Great Bay Bio (hereinafter referred to as “GBB”), Pebble Accelerator (a subsidiary of Tigermed, hereinafter referred to as “Pebble”) and Uni-Bio Science Group Co., Ltd. (00690.HK, hereinafter referred to as “Uni-Bio”) officially signed a project cooperation agreement on jointly developing new weight loss drugs. The three parties will collaborate to innovate and build a complete ecological industrial chain of “Target discovery - Antibody generation - Druggability verification - Process development - Clinical pipeline stage – Commercialization”, and jointly explore and create a new therapeutic driving force for new target antibody drugs in the field of weight loss.Representatives from the Hong Kong Science and Technology Park (HKSTP), Hong Kong’s largest science and technology business incubation base, attended the event to witness this event.
Dr. Kane, CCO of GBB, Mr. Emmanual Hui, CEO of Pebble, and Dr. Yu, R&D Director of Uni-Bio signed the contract on behalf of the company. Kenneth Lai, Chief Financial Officer of Great Bay Bio, WengLi You, Assocate Director of HKSTP, Grace Lau, Head of ITR, HKSTP, Dr. Patrick Lau, Deputy Executive Director of HKTDC, Ken Young, Yeung Ka Wei and Justin Lam from Uni-Bioscience attended and witnessed the moment together.
Based on the company's super-powerful artificial intelligence platform, GBB's AI antibody design platform make in-depth use of the "Fast Follow" and "First in Class" methods for antibody design, and directly predicts the structure of proteins through their amino acid sequence and provides a visual interface. It has broken through the industry's technical bottlenecks in terms of antibody generation, evaluation, and transformation, significantly reducing R&D trial and error costs and accelerating the process of new drug R&D. GBB was successfully admitted into the Elite Programme by HKSTP in May 24, 2023.
Committed to utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long timelines, high costs, and low success rates in drug development. AlfaBodY, an antibody sequence generation platform that can reduce wet lab work and develope humanized sequence efficiently; AlfaDAX, a bio-product molecule design and optimization platform, enables customers to quickly screen and modify protein candidates before they enter the CMC stage, reducing trial and error costs and accelerating the development of new drugs; AlfaCell, a site-specific integration cell line platform, accurately insert the target genes into specific “hot spot”, complete RCB construction in 1.5 months; AlfaOPA, an one-step cell culture media development platform, complete in a single step by adding optimized supplements to the existing culture media.
At the same time, based on the strong ecosystem of Pebble and the efficient production platform and marketing network of Uni-Bio, the three parties will complement each other's strengths and fully integrate the advantageous resources in drug development, clinical trials and marketing to jointly promote this landmark antibody drug to enter the clinical stage. This antibody drug can reduce or avoid many side effects that current drugs bring to patients, such as nausea, loss of appetite, suicidal tendencies, weight rebound after drug withdrawal, muscle loss, high frequency of administration, etc., seizing the tens of billions of dollars market in the field of weight loss, bringing new well-being to patients.
About Pebble Accelerator
Pebble Accelerator by Tiger Jade is a visionary accelerator at the forefront of the life sciences sector, driven by its core values of innovation, collaboration, and impact. Pebble's mission is to empower emerging biotech ventures through a comprehensive suite of services and functions tailored to their needs. From strategic consulting to early-stage investments, Pebble provides unparalleled support to propel ventures to success. With a robust network cultivated through strategic partnerships with industry leaders, including Tigermed, our biggest supporter, Pebble offers unparalleled strategic value, connecting ventures with vital resources, expertise, and opportunities. Explore more about Pebble and its transformative initiatives at https://pebbleaccelerator.com/.
About Uni-Bio Science Group
Uni-Bio Science Group is principally engaged in the research and development, manufacturing and distribution of pharmaceutical products. The Group's research and development center is equipped with a complete system for the research and development of genetically engineered drugs, a pilot plant and a quality control system in compliance with the requirements of the State Drug Administration. The Group also has a production base in Beijing and a production base in Shenzhen which comply with the Current Good Manufacturing Practice (cGMP). The Group also has an efficient commercialization platform and marketing network. The Group specializes in the research and development of innovative therapeutic drugs for diabetes, osteoporosis and other endocrinology, ophthalmology and dermatology. For more information, please visit the official website of Uni-Bio Science Group: www.uni-bioscience.com.
